JP2015120758A5 - - Google Patents

Download PDF

Info

Publication number
JP2015120758A5
JP2015120758A5 JP2015068513A JP2015068513A JP2015120758A5 JP 2015120758 A5 JP2015120758 A5 JP 2015120758A5 JP 2015068513 A JP2015068513 A JP 2015068513A JP 2015068513 A JP2015068513 A JP 2015068513A JP 2015120758 A5 JP2015120758 A5 JP 2015120758A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral administration
dose oral
hydrate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015068513A
Other languages
Japanese (ja)
Other versions
JP6142892B2 (en
JP2015120758A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2015068513A priority Critical patent/JP6142892B2/en
Priority claimed from JP2015068513A external-priority patent/JP6142892B2/en
Publication of JP2015120758A publication Critical patent/JP2015120758A/en
Publication of JP2015120758A5 publication Critical patent/JP2015120758A5/ja
Application granted granted Critical
Publication of JP6142892B2 publication Critical patent/JP6142892B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (8)

ミノドロン酸もしくは製薬学的に許容されるその塩又はその水和物を含有し、ミノドロン酸もしくは製薬学的に許容されるその塩又はその水和物の平均粒子径が1μm以上20μm以下である、高用量経口投与用医薬組成物。 Minodronic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof, and the average particle size of minodronic acid or a pharmaceutically acceptable salt or hydrate thereof is 1 μm or more and 20 μm or less . A pharmaceutical composition for high dose oral administration. 溶出試験開始後15分後の薬物溶出率が80％以上である、請求項１に記載の高用量経口投与用医薬組成物。The pharmaceutical composition for high-dose oral administration according to claim 1, wherein the drug dissolution rate 15 minutes after the start of the dissolution test is 80% or more. ミノドロン酸もしくは製薬学的に許容されるその塩又はその水和物を医薬組成物中に0.1重量％以上50重量％以下含有する、請求項１または２に記載の高用量経口投与用医薬組成物。   The pharmaceutical composition for high-dose oral administration according to claim 1 or 2, wherein minodronic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof is contained in the pharmaceutical composition in an amount of 0.1 wt% to 50 wt%. . ミノドロン酸もしくは製薬学的に許容されるその塩又はその水和物を医薬組成物中に10mg以上1g以下含有する、請求項１乃至３のいずれか一項に記載の高用量経口投与用医薬組成物。   The pharmaceutical composition for high-dose oral administration according to any one of claims 1 to 3, which contains 10 mg or more and 1 g or less of minodronic acid or a pharmaceutically acceptable salt or hydrate thereof in the pharmaceutical composition. object. 更に、クロスカルメロースナトリウム、クロスポビドン、カルボキシメチルスターチナトリウムからなる群より選択される１、または２以上の物質を含有する、請求項１乃至４のいずれか一項に記載の高用量経口投与用医薬組成物。 The high-dose oral administration according to any one of claims 1 to 4 , further comprising one or more substances selected from the group consisting of croscarmellose sodium, crospovidone, and sodium carboxymethyl starch. Pharmaceutical composition. 前記物質の量が、医薬組成物の重量に対して5重量％以上50重量％以下である、請求項５に記載の高用量経口投与用医薬組成物。 The pharmaceutical composition for high dose oral administration according to claim 5 , wherein the amount of the substance is 5% by weight or more and 50% by weight or less based on the weight of the pharmaceutical composition. 経口投与用医薬組成物が、錠剤である、請求項１乃至６のいずれか一項に記載の高用量経口投与用医薬組成物。   The pharmaceutical composition for high dose oral administration according to any one of claims 1 to 6, wherein the pharmaceutical composition for oral administration is a tablet. 平均粒子径が1μm以上20μm以下であるミノドロン酸もしくは製薬学的に許容されるその塩又はその水和物を造粒する工程、及び該造粒物に各種添加剤を含み圧縮成型する工程、を含む、請求項１に記載の高用量経口投与用医薬組成物の製造方法。   A step of granulating minodronic acid having a mean particle size of 1 μm or more and 20 μm or less, or a pharmaceutically acceptable salt or hydrate thereof, and a step of compression-molding the granule containing various additives. The manufacturing method of the pharmaceutical composition for high dose oral administration of Claim 1 containing.
JP2015068513A 2011-06-20 2015-03-30 Pharmaceutical composition for oral administration Active JP6142892B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015068513A JP6142892B2 (en) 2011-06-20 2015-03-30 Pharmaceutical composition for oral administration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011136218 2011-06-20
JP2011136218 2011-06-20
JP2015068513A JP6142892B2 (en) 2011-06-20 2015-03-30 Pharmaceutical composition for oral administration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012138410A Division JP5874545B2 (en) 2011-06-20 2012-06-20 Pharmaceutical composition for oral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017031568A Division JP2017088626A (en) 2011-06-20 2017-02-22 Pharmaceutical compositions for oral administration

Publications (3)

Publication Number Publication Date
JP2015120758A JP2015120758A (en) 2015-07-02
JP2015120758A5 true JP2015120758A5 (en) 2015-08-13
JP6142892B2 JP6142892B2 (en) 2017-06-07

Family

ID=47785990

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012138410A Active JP5874545B2 (en) 2011-06-20 2012-06-20 Pharmaceutical composition for oral administration
JP2015068513A Active JP6142892B2 (en) 2011-06-20 2015-03-30 Pharmaceutical composition for oral administration
JP2017031568A Withdrawn JP2017088626A (en) 2011-06-20 2017-02-22 Pharmaceutical compositions for oral administration
JP2018007905A Active JP6455611B2 (en) 2011-06-20 2018-01-22 Pharmaceutical composition for oral administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012138410A Active JP5874545B2 (en) 2011-06-20 2012-06-20 Pharmaceutical composition for oral administration

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017031568A Withdrawn JP2017088626A (en) 2011-06-20 2017-02-22 Pharmaceutical compositions for oral administration
JP2018007905A Active JP6455611B2 (en) 2011-06-20 2018-01-22 Pharmaceutical composition for oral administration

Country Status (1)

Country Link
JP (4) JP5874545B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190104590A (en) * 2017-01-13 2019-09-10 닛뽄세이시가부시끼가이샤 Micro Spherical Lip
TW202241409A (en) * 2020-12-18 2022-11-01 南韓商大熊製藥股份有限公司 New formulation comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine for the oral administration
CN112972400A (en) * 2021-03-09 2021-06-18 华侨大学 Rapidly disintegrable minodronic acid granules and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4100723B2 (en) * 1995-07-10 2008-06-11 旭化成ケミカルズ株式会社 Granule and its production method
EP0998932A1 (en) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Solid pharmaceutical dosage form containing diphosphonates or their salts and method for its production
SE9901272D0 (en) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
JP4394888B2 (en) * 2002-02-14 2010-01-06 救急薬品工業株式会社 Transdermal formulation
KR100642961B1 (en) * 2002-05-10 2006-11-10 에프. 호프만-라 로슈 아게 Bisphosphonic acid for the treatment and prevention of osteoporosis
WO2005072747A1 (en) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. Bone resorption inhibitors
JP2008533173A (en) * 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミテッド Nanoparticulate bisphosphonate composition
JP2007314529A (en) * 2006-04-28 2007-12-06 Lion Corp Granulated particle, tablet and method for producing granulated particle
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
IN2012DN00954A (en) * 2009-07-28 2015-04-10 Takeda Pharmaceutical

Similar Documents

Publication Publication Date Title
JP2018162255A5 (en)
RU2018114447A (en) INTRODUCTION OF CFTER DUTERED AMPLIFIERS
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
EA031255B1 (en) Delayed release cysteamine bead formulation and methods for the preparation and use thereof
JP2015510916A5 (en)
JP2016539953A5 (en)
TWI700100B (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
JP2015511635A5 (en)
JP2016513724A5 (en)
JP2016540021A5 (en)
SI2729130T1 (en) Darunavir combination formulations
JP2014221827A5 (en)
HRP20131088T1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2012053785A3 (en) Sustained-release pellets containing tacrolimus as an active ingredient
JP2018039810A5 (en)
JP2015120758A5 (en)
JP2016512247A5 (en)
WO2015132708A1 (en) Pharmaceutical composition of roflumilast
JP2015521647A5 (en)
EP3648745A4 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
JP2017523149A5 (en)
JP2016530238A5 (en)
JP2017513866A5 (en)
JP2017520619A5 (en)
EA033291B1 (en) Dosage unit comprising ramipril and bisoprolol hemifumarate, process for the preparation thereof and method of treating hypertension